Zika virus vaccine - Protein Sciences Corporation

Drug Profile

Zika virus vaccine - Protein Sciences Corporation

Alternative Names: Zikavirus vaccine

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Immunobiological Technology Institute; Laboratorios Liomont; Mundo Sano; National Institute of Allergy and Infectious Diseases; Protein Sciences Corporation; Sinergium Biotech; UMN Pharma
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection

Most Recent Events

  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
  • 12 Jan 2017 Protein Sciences and Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) agree to co-develop Zika virus vaccine in Brazil for Zika virus infection (Prevention)
  • 12 Jan 2017 Early research in Zika virus infection (Prevention) in Brazil (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top